This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Joan Stephenson, PhD

JAMA. 2001;285:2841-2842.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—Successful trials of a drug designed to counter the deadly genetic glitches responsible for two forms of cancer portend a coming wave of novel therapies that will transform the way cancer is treated, said researchers gathered here for the annual meeting of the American Society of Clinical Oncology (ASCO).

The new therapies, the result of decades of basic research aimed at understanding the molecular biology of cancer, herald "the beginning of a sea change in how we practice cancer medicine," said ASCO President Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, New York.

Such molecularly targeted therapies are expected to be the pharmaceutical equivalent of a smart bomb, homing in on a defined target and inflicting far less of the collateral damage to noncancerous cells than results from conventional chemotherapy and radiation.

But because many malignancies may be caused by an accumulation of gene mutations, . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi and Myers
J. Dent. Res. 2008;87:14-32.
ABSTRACT | FULL TEXT  

Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer
Holsinger et al.
Clin. Cancer Res. 2003;9:3183-3189.
ABSTRACT | FULL TEXT